REGENERON PHARMACEUTICALS, INC. — Form 10-Q
Filed July 30, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Leonard S. Schleifer (CEO) and Christopher Fenimore (CFO) certified on July 30, 2026 that the Q2 2026 10-Q for the period ended June 30, 2026 contains no material untrue statements, fairly presents financial condition and results, and that disclosure controls and internal controls over financial reporting are effectively designed and maintained. No specific operational, financial, or strategic changes are disclosed in these certification exhibits.
Why this rating
Standard Sarbanes-Oxley certifications; routine quarterly filing compliance document with no substantive business events, transactions, or disclosures.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.